Original research

Embotrap Extraction & Clot Evaluation & Lesion Registry design and methods

Adnan H Siddiqui 1, Muhammad Waqas 2, Waleed Brinjikji 3, Simon De Meyer 4, Karen Doyle 5, Jens Fiehler 6, Werner Hacke 7, Ricardo A Hanel 8, Tudor G Jovin 9, David S Liebeskind 10, Albert J Yoo 11, Osama O Zaidat 12, Tommy Andersson 13,14, Raul G Nogueira 15

ABSTRACT

Background Relationships between occlusive clot histopathology, baseline characteristics, imaging findings, revascularization rates, and clinical outcomes of stroke patients with large vessel occlusion (LVO) are not well understood. This study will assess the real-world experience on the efficacy and safety of using the EmboTrap device as the first approach in LVO patients and explore the associations between clot histological characteristics, imaging and clinical findings, revascularization rates, and clinical outcomes.

Methods Prospective, global, multicenter, single-arm, imaging core laboratory, and clot analysis central laboratory observational registry. Adult patients (>18 years) with LVO, treated with EmboTrap as the first attempted device, will be eligible for study participation.

Results Up to 1000 subjects at 50 international sites may be enrolled. Occlusive clots will be collected from at least 500 subjects. Independent central and imaging core laboratories will perform clot analysis and image adjudication. Statistical analysis will assess the association between imaging and clinical findings, clot characteristics, subject comorbidities, revascularization, and clinical outcomes. Study endpoints are functional independence (modified Rankin Scale score ≤2 at 90 days), expanded Thrombolysis In Cerebral Infarction (eTICI) score ≥2b/3, first-pass effect, number of passes, embolization into new territory, symptomatic intracranial hemorrhage, and 90-day mortality.

Conclusions The EXCELLENT registry will provide reproducible effectiveness and safety data of EmboTrap for its use for mechanical thrombectomy. Additionally, the study will characterize the blood clots retrieved during mechanical thrombectomy with respect to their composition and histopathological analysis and potential correlations with clinical and imaging findings.

Trial registration number NCT03685578.

BACKGROUND

According to the World Health Organization, 15 million people suffer from a stroke per year, leaving 5 million dead and 5 million severely disabled.1 Approximately 90% of all strokes are acute ischemic strokes (AIS). Estimates on the percentage of AIS due to large vessel occlusion (LVO)—internal carotid artery, middle cerebral artery, vertebral artery, and basilar artery—vary from 15.8% to 46% depending on the definition methodology and nature of the screened population.2 Meta-analyses of randomized controlled trials successfully demonstrated the safety and effectiveness of mechanical thrombectomy (MT) compared with medical therapy alone in treating AIS in patients secondary to LVOs.3 As a result, treatment guidelines recommended MT as the standard of care.4 Trials included in the HERMES pooled analysis used stent retrievers such as Trevo and Solitaire FR. While these devices were safe and effective in the treatment of AIS, successful revascularization was not achieved in a subset of patients.3,5,6 The SEERS and HERMES pooled analysis of all randomized controlled trials reported a revascularization rate (modified Thrombolysis In Cerebral Infarction (mTICI) 2b/3) of 71%.2 However, complete reperfusion (Thrombolysis In Cerebral Infarction (TICI) 3) on first pass was achieved in only 33%. It is hypothesized that anatomical variations and clot characteristics are contributing factors to achieving complete revascularization, underscoring the need for additional advances in MT devices.7 Therefore, it is important to evaluate predictors of failed revascularization.

The EmboTrap Revascularization Device (Neuravi/Cerenovus) was designed specifically to perform across a range of clots with varying characteristics in the anterior and posterior neurovasculature. EmboTrap is delivered, unsheathed, and deployed in a fashion similar to other MT devices on the market. It traps the clot within the petals, thus allowing successful retrieval of the clot and restoration of blood flow.8

Previous international, multicenter clinical trials on the use of the EmboTrap Revascularization Device, that is, ARISE and ARISE II, showed impressive rates of final successful revascularization (mTICI 2b–3) of 95% and 93%, respectively. In the ARISE II study, 80% of the subjects enrolled achieved successful revascularization (mTICI ≥2b/3) within three device passes. Overall, 67% of the subjects in ARISE II achieved a modified Rankin Scale (mRS) score of 0–2 at 90 days.9
To demonstrate the reproducibility of these results, the Embotrap Extraction & Clot Evaluation & Lesion Evaluation for NeuroThrombectomy (EXCELLENT) Real-world International Registry was initiated. The primary objective of the study is to evaluate the efficacy and safety of the Embotrap Revascularization Device independently and before enrollment in the research study. The secondary objective is to explore the associations between baseline imaging characteristics, clot histology, and subject comorbidities with clinical and revascularization outcomes. Here we present the methodology of the EXCELLENT registry.

METHODS/DESIGN

Design
This is a prospective, global, multicenter, single-arm, observational registry. Per agreement with the Food and Drug Administration (FDA), the registry will be conducted under an investigational device exemption. The registry will enroll patients at 50 sites in the USA, Europe, and other regions (participating sites are listed in online supplemental table 1).

Patient population: inclusion and exclusion criteria
Patients with angiographically confirmed LVO, undergoing MT with Embotrap as the first attempt device for the intracranial occlusion, will be included in the study. Full and detailed eligibility criteria are presented in box 1.

Intervention
Eligible patients will be enrolled after signing an informed consent in accordance with local regulations and institutional review board/ethics committee (IRB/EC) protocol (IRB/EC approval information is provided in online supplemental table 1). Due to the emergent nature of AIS, if approved by IRB/EC consent may be obtained after the procedure but prior to 7 days or if not approved consent will be obtained pre-procedure (study flow chart is outlined in figure 1). The enrolled subject will undergo endovascular MT with the Embotrap Revascularization Device as the first attempted treatment device for the intracranial occlusion. The minimum required number of MT passes with Embotrap is one. The treating interventionist may decide to use any other device or technique if reperfusion is not achieved with Embotrap. Thrombectomy devices (eg, use of stent retriever, aspiration, balloon guide, intermediate catheter, long sheath catheter) along with technique details (eg, incubation time, device positioning, co-aspiration) as well as rates and reasons for device changes, will be captured for each procedural pass.

Clot collection and analysis at independent central laboratory
Blood clot retrieved during each pass of the stent retriever will be collected at sites with infrastructure for clot collection and transfer (online supplemental table 1). Clots will be collected from a minimum of 500 subjects. Clots retrieved with each pass will be collected separately in neutral buffered formalin solution and de-identified for transport. Composition and histopathological analysis of clots will be performed at an independent central laboratory. Relative content of red blood cells (RBC), white blood cells, platelets, fibrin and other fibrous proteins will be evaluated by experts in the laboratory. Successful achievement of this endpoint will facilitate analysis of effective removal of clots that span the range from RBC-rich (75%) to RBC-poor (<25%). Hematoxylin and eosin (H&E) staining will also be conducted and scans made available for analysis.

Box 1 Inclusion and exclusion criteria

Inclusion criteria:
- Candidates for this study must meet ALL of the following criteria:
  - Age ≥18 years
  - Informed consent
  - Subjects experiencing AIS with angiographic confirmation of LVO
  - A clinical decision made to use the Embotrap Revascularization Device independently and before enrollment in the research study
  - Embotrap Revascularization Device is the first attempted device/technique for MT in the subject.

Exclusion criteria:
- Subjects will be excluded if ANY of the following apply:
  - Participation in a clinical trial that may confound study endpoints
  - Positive pregnancy test.

Subgroup comparable to previous studies utilizing MT:
A subgroup of subjects will be identified through pre-specified eligibility criteria consistent with studies utilized for regulatory clearance of thrombectomy devices in the USA.
- mRS ≤1
- NIHSS ≥8 and <30
- Occlusion location=ICA, M1 or M2
- ASPECTS ≥6
- Subjects treated within 6 hours hours of onset of AIS
- Subjects who did not receive IV thrombolysis or received it within 3 hours of AIS onset
- Subjects that did not undergo carotid stenting or angioplasty.

AIS, acute ischemic stroke; ASPECTS, Alberta Stroke Program Early CT Score; ICA, internal carotid artery; IV thrombolysis, intravenous tissue plasminogen activator; LVO, large vessel occlusion; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale.

Figure 1 Schematic of study design—flow chart. AE/s, adverse events; ICF, informed consent form; IV-tPA, intravenous tissue plasminogen activator; LVO, large vessel occlusion; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.
Independent core imaging laboratory

An independent core laboratory will perform blinded assessments of imaging parameters at entry, and the assessments for the primary and secondary imaging endpoints, including eTICI, infarct volume, intracerebral hemorrhage (ICH) type along with emboli in new territory. These evaluations will be performed by experienced independent readers. Figure 2 illustrates the role of the independent core laboratory.

Functional outcomes

Functional independence will be assessed by mRS (mRS ≤2) at 90±15 days performed by a qualified evaluator independent of the interventional treating team.

Clinical efficacy

Clinical efficacy outcomes of the study are: (1) mRS 0–2 at 90 days or equal to pre-stroke mRS value; (2) change in the National Institutes of Health Stroke Scale (NIHSS) score at 24 hours compared with baseline; (3) death due to any cause at 90 days.

Performance outcome will be successful revascularization with final eTICI ≥2b. Other performance parameters will include final revascularization with eTICI ≥2c, first pass effect (eTICI ≥2c after the first pass without rescue), modified first pass effect (eTICI ≥2b50 after the first pass), procedure time defined as time from groin puncture to revascularization, and occurrence of embolization to a new territory.

Imaging analysis

Other parameters, including clot composition and histopathologic analysis, will be performed.

Clot analysis

Safety endpoints will include symptomatic ICH at 24 hours, safety analysis population (all patients in whom the treatment is attempted) and modified intent to treat population (all patients who received treatment). Safety analysis will be performed for the mRS sub-population.

Sample size estimates

Up to 1000 subjects will be enrolled, keeping with the therapeutic area standards for similar post-market registries. Clot collection is expected to be achieved in a minimum of 500 subjects, based on projected enrollment at the contributing sites. The sample size for a subgroup analysis has also been specified. A minimum of 184 consecutive subjects enrolled into this study will be identified through pre-specified eligibility criteria in order to define a cohort similar with regard to pre-stroke mRS, baseline NIHSS and clot location to those enrolled in prior MT studies (defined as the mRS sub-population). Based on the ARISE II study outcomes and the real-world setting for the study, the anticipated proportion of subjects reaching mRS score 0–2 at day 90 ranges between 53–55%. Approximately 184 subjects will be needed to obtain at least 80% power to compare the proportion of subjects with mRS score 0–2 at day 90 to a performance goal of 41.3% (established from a meta-analysis of MR CLEAN, TREVO 2, SWIFT and SWIFT PRIME) at a one-sided α of 2.5%, using the exact method. The assumed attrition is 20% to account for subjects who are lost to follow-up, early withdrawal or have missing outcomes.

Statistical analyses

Statistical analysis will be performed using SAS version 9.4.

Standard descriptive summaries for continuous data include mean, standard deviation, minimum, median, and maximum values. For categorical data, the count and percentage will be provided. All demographic characteristics, procedural, imaging, postoperative data, and clot data will be summarized in the safety analysis population (all patients in whom the treatment is attempted) and modified intent to treat population (all patients who received treatment).

When the study is completed, the following analysis will be performed for the mRS sub-population. The number and percentage of subjects reaching mRS score 0–2 at day 90 will be summarized. The exact two-sided 95% confidence intervals will be constructed around the percentage and the lower bound of the confidence intervals will be compared with the performance goal of 41.3%. Missing mRS scores at day 90 will be handled with the use of the last-observation-carried-forward approach when a score is available from a post-procedure visit (eg, 7 days/ discharge or unscheduled visit). Live subjects who are missing any mRS scores post-baseline will be excluded from the analysis.

The χ² test will be used when the expected cell frequency is >5 (or Fisher’s exact test otherwise) for categorical variables and the t-test when the normality assumption is met (or other
non-parametric tests as appropriate, for example, the Mann-Whitney U test) for comparison of numerical variables.

A periodic analysis (eg, annual, or more frequently based on enrollment) is planned to report data on the endpoints descriptively which may also be used for presentations at scientific meetings. Exploratory analyses will be performed in the clot population between: (1) baseline subject comorbidity and clot characteristics (clot characteristics as dependent variables); (2) clot characteristics and reperfusion (reperfusion as the dependent variable); and (3) baseline subject comorbidities, clot characteristics and reperfusion with clinical outcomes (clinical outcomes as dependent variables).

**Measures to minimize bias**

In addition to standardized independent central clot and core imaging laboratories, the following measures are planned to minimize bias:

1. An independent clinical events committee will review all safety endpoints and other adverse events of interest including all 24-hour ICHs
2. Neurological status and clinical outcomes will be assessed by certified evaluators using NIHSS and mRS which are standardized objective tools widely used in neurological research
3. The 90-day mRS will be performed by a qualified independent evaluator who is not part of the interventional treating team
4. Study monitors will have clinical research experience and be proficient at study monitoring. Study data will be source data verified using the subject’s medical records, study source worksheets, clinic notes, and radiographic reports as applicable.

**Study organization and funding**

Study conduct will be overseen by the executive steering committee and the sponsor. The executive steering committee will be led by three global co-principal investigators. The steering committee will be comprised of experts in the field of stroke intervention and representatives of leading enrolling sites. Cerenovus will provide funding for the study.

**DISCUSSION**

The EXCELLENT registry will provide reproducible effectiveness and safety data of EmboTrap for its use for MT in a large prospective, global cohort of patients in real-world setting across different sites and operator experience levels. Additionally, the study will characterize the blood clots retrieved during MT with respect to their composition and histopathological analysis and potential correlations to clinical and imaging findings.

The composition of the clot determines its physical properties and may influence the rates of successful MT. Clots are tough in consistency. In vitro MT models have indicated a high failure rate with existing stent retrievers for fibrin-rich clots. Information on the composition and characteristics of clots retrieved during endovascular procedures is limited. EXCELLENT will provide a large repository of endovascularly obtained clots, intended to improve our understanding of clot properties and possible correlations to clinical, procedural, and imaging characteristics. Compared with other large repositories of thrombi retrieved in MT, this study additionally includes the collection of per pass device and technique details, use of an independent imaging core laboratory, and functional outcomes assessment by a qualified evaluator independent of the interventional treating team. The insights obtained will be used to improve the design of existing stent retrievers and refine the technique for MT.

The current study is designed to have a subgroup with predefined eligibility criteria, consistent with previous clinical trials on MT. This subgroup will be used to compare the results of EXCELLENT with studies used for recent clearances by regulatory agencies in the USA.

Another strength of the study is the use of independent central and imaging laboratories to evaluate the clot and imaging data from study subjects, and independent assessment of clinical outcomes. EXCELLENT will not restrict enrollment of patients currently being treated per standard of care, providing prospective real-world data on the effectiveness of EmboTrap in subjects receiving MT per the latest American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation/European Society for Minimally Invasive Neurological Therapy (ESO/ESMINT) guidelines.

Furthermore, the EXCELLENT real-life MT registry may include patients who are treated per routine care even though they do not fit the current guidelines, with good sample size to explore the efficacy and safety of EmboTrap in this population that may be harder to study in randomized clinical trials otherwise.

**CONCLUSIONS**

EXCELLENT is a prospective global registry designed to assess the effectiveness via real-world experience of the EmboTrap stent retriever and to explore the associations between imaging characteristics at presentation, clot characteristics, subject comorbidities, clinical outcomes, and revascularization rates.

**Author affiliations**

1 University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
2 Neurosurgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
3 Mayo Clinic Minnesota, Rochester, Minnesota, USA
4 Laboratory for Thrombosis Research, KU Leuven, Campus Kulak Kortrijk, Kortrijk, Belgium
5 Physiology, CURAM, National University of Ireland Galway, Galway, Ireland
6 Dept. of Neuroradiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
7 Neurology, University of Heidelberg, Heidelberg, Germany
8 Lyerly Neurosurgery, Baptist Medical Center Downtown, Jacksonville, Florida, USA
9 Neurology, Cooper University Hospital, Camden, New Jersey, USA
10 Neurology, UCLA, Los Angeles, California, USA
11 Neurointervention, Texas Stroke Institute, Plano, Texas, USA
12 Neuroscience, St Vincent Mercy Hospital, Toledo, Ohio, USA
13 Departments of Radiology and Neurology, AZ Groeninge, Kortrijk, Belgium
14 Departments of Neuroradiology, Department of Clinical Neuroscience, Karolinska University Hospital; Karolinska Institutet, Stockholm, Sweden
15 Grady Memorial Hospital, Chickasha, Georgia, USA

**Twitter**

Jens Fiehler @Fie0815

**Contributors**

AHS, WR, SDeM, KD, JF, WH, TGi, DSl, AIJ, OQZ, TA, and RGN conceptualized the study and developed the methodology. MW wrote the original draft of the protocol. AHS, TA and RGN provided study supervision. All authors reviewed, edited, and approved the final draft of the protocol.

**Funding**

The EXCELLENT study is sponsored by Cerenovus (Irvine, California, USA).

**Competing interests**

AHS: Co-investigator NIH/NINDS 1R01NS091075; Amnis Therapeutics, Boston Scientific, Caron Medical Systems USA Inc, Cerebrotech Medical Systems, Cerenovus, Corinex Inc, EndoStream Medical Ltd, Guidepoint Global Consulting, Imperative Care, Integra LifeSciences Corp, Medtronic, MicroVention, Q’Apel Medical Inc, Rapid Medical, Rebound Therapeutics Corp, Serenity Medical Inc, Silk Road Medical, SlimMed, Styrer, Three Rivers Medical, VascuLX, Gore & Associates; Amnis Therapeutics, Apama Medical, Blink TBI Inc, Buffalo Technology Partners Inc, Cardinal Consultants, Cerebrotech Medical Systems, Cognition Medical, Endostream Medical Ltd, Imperative Care, International Medical Distribution Partners, Neurovascular Diagnostics Inc, Q’Apel Medical Inc, Rebound Distribution Partners, Neurovascular Diagnostics Inc, Q’Apel Medical Inc, Rebound Development Partners, Neurovascular Diagnostics Inc, Q’Apel Medical Inc, Rebound...

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no datasets generated and/or analyzed for this study.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any errors and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use and license their derivative works on different terms, provided the original work is

ORCID iDs


REFERENCES


